Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Feb;62(2):97–99. doi: 10.1136/ard.62.2.97

Predictors of end stage lung disease in systemic sclerosis

V Steen 1
PMCID: PMC1754422  PMID: 12525376

Full Text

The Full Text of this article is available as a PDF (78.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Badesch D. B., Tapson V. F., McGoon M. D., Brundage B. H., Rubin L. J., Wigley F. M., Rich S., Barst R. J., Barrett P. S., Kral K. M. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000 Mar 21;132(6):425–434. doi: 10.7326/0003-4819-132-6-200003210-00002. [DOI] [PubMed] [Google Scholar]
  2. Greidinger E. L., Flaherty K. T., White B., Rosen A., Wigley F. M., Wise R. A. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest. 1998 Sep;114(3):801–807. doi: 10.1378/chest.114.3.801. [DOI] [PubMed] [Google Scholar]
  3. Kinuya K., Nakajima K., Kinuya S., Michigishi T., Tonami N., Takehara K. Esophageal hypomotility in systemic sclerosis: close relationship with pulmonary involvement. Ann Nucl Med. 2001 Apr;15(2):97–101. doi: 10.1007/BF02988598. [DOI] [PubMed] [Google Scholar]
  4. MacGregor A. J., Canavan R., Knight C., Denton C. P., Davar J., Coghlan J., Black C. M. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001 Apr;40(4):453–459. doi: 10.1093/rheumatology/40.4.453. [DOI] [PubMed] [Google Scholar]
  5. Morelli S., Barbieri C., Sgreccia A., Ferrante L., Pittoni V., Conti F., Gualdi G., Polettini E., Carlesimo O. A., Calvieri S. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol. 1997 Jan;24(1):81–85. [PubMed] [Google Scholar]
  6. Morgan C., Knight C., Lunt M., Black C. M., Silman A. J. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis. 2003 Feb;62(2):146–150. doi: 10.1136/ard.62.2.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Okano Y., Steen V. D., Medsger T. A., Jr Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med. 1993 Nov 15;119(10):1005–1013. doi: 10.7326/0003-4819-119-10-199311150-00007. [DOI] [PubMed] [Google Scholar]
  8. Peters-Golden M., Wise R. A., Schneider P., Hochberg M., Stevens M. B., Wigley F. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine (Baltimore) 1984 Jul;63(4):221–231. doi: 10.1097/00005792-198407000-00004. [DOI] [PubMed] [Google Scholar]
  9. Rubin Lewis J., Badesch David B., Barst Robyn J., Galie Nazzareno, Black Carol M., Keogh Anne, Pulido Tomas, Frost Adaani, Roux Sebastien, Leconte Isabelle. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21;346(12):896–903. doi: 10.1056/NEJMoa012212. [DOI] [PubMed] [Google Scholar]
  10. Silver R. M. Scleroderma. Clinical problems. The lungs. Rheum Dis Clin North Am. 1996 Nov;22(4):825–840. doi: 10.1016/s0889-857x(05)70303-3. [DOI] [PubMed] [Google Scholar]
  11. Steen V. D. Autoantibodies in systemic sclerosis. Bull Rheum Dis. 1996 Oct;45(6):6–8. [PubMed] [Google Scholar]
  12. Steen V. D., Conte C., Owens G. R., Medsger T. A., Jr Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994 Sep;37(9):1283–1289. doi: 10.1002/art.1780370903. [DOI] [PubMed] [Google Scholar]
  13. Steen V. D., Graham G., Conte C., Owens G., Medsger T. A., Jr Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum. 1992 Jul;35(7):765–770. doi: 10.1002/art.1780350709. [DOI] [PubMed] [Google Scholar]
  14. Steen V. D., Medsger T. A., Jr Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000 Nov;43(11):2437–2444. doi: 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  15. Steen V. D., Owens G. R., Fino G. J., Rodnan G. P., Medsger T. A., Jr Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum. 1985 Jul;28(7):759–767. doi: 10.1002/art.1780280706. [DOI] [PubMed] [Google Scholar]
  16. Steen V. D., Powell D. L., Medsger T. A., Jr Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988 Feb;31(2):196–203. doi: 10.1002/art.1780310207. [DOI] [PubMed] [Google Scholar]
  17. Stupi A. M., Steen V. D., Owens G. R., Barnes E. L., Rodnan G. P., Medsger T. A., Jr Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 1986 Apr;29(4):515–524. doi: 10.1002/art.1780290409. [DOI] [PubMed] [Google Scholar]
  18. Tashkin D. P., Clements P. J., Wright R. S., Gong H., Jr, Simmons M. S., Lachenbruch P. A., Furst D. E. Interrelationships between pulmonary and extrapulmonary involvement in systemic sclerosis. A longitudinal analysis. Chest. 1994 Feb;105(2):489–495. doi: 10.1378/chest.105.2.489. [DOI] [PubMed] [Google Scholar]
  19. White B., Moore W. C., Wigley F. M., Xiao H. Q., Wise R. A. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000 Jun 20;132(12):947–954. doi: 10.7326/0003-4819-132-12-200006200-00004. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES